Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapacitabine in Elderly AML
NCT01303796Phase 3Completed
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Oct 2011
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of sapacitabine in acute myeloid leukemia (AML) (2 arms), sponsored by Cyclacel Pharmaceuticals, Inc. Primary endpoint: Overall Survival at 43 months. Started Oct 2011; status: completed.
02
Drugs
sapacitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01303796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01303796.